Acrigen Biosciences develops precision gene editing systems utilizing proprietary αCas and μCas CRISPR-Cas nucleases paired with engineered anti-CRISPR proteins to enhance the accuracy and safety of genetic therapies. The company aims to address genetic disorders by providing targeted and efficient gene editing solutions for human therapeutics.

Bicara Therapeutics develops dual-action cancer therapies that combine a bifunctional EGFR/TGF-β antibody with tumor microenvironment modulators to enhance treatment efficacy for solid tumors, particularly head and neck squamous cell carcinoma. This approach aims to improve patient outcomes by providing targeted therapies that offer meaningful and durable benefits.

The startup operates a diagnostic test clinic that utilizes in-depth health analysis and personalized data assessments to evaluate client longevity. By providing actionable insights and annual reassessments at an affordable cost, the company enables clients to understand their health risks and improve their long-term well-being.

CARGO Therapeutics is developing tri-specific CAR T-cell therapies designed to target and eliminate B-cell lymphoma cells effectively. This approach aims to provide patients with potentially curative treatment options that traditional therapies may not achieve.

Ceribell provides a point-of-care electroencephalography (EEG) system that generates standardized and detailed EEG reports to facilitate rapid assessment of seizure activity in critically ill patients. This technology enhances the efficiency of diagnosis and treatment in emergency departments and ICUs, ultimately improving patient outcomes and reducing ICU stay lengths.

Engrail Therapeutics develops precision-targeted therapeutics for patients with life-limiting neurological disorders by leveraging expertise in molecular mechanisms and neurocircuitry. The company aims to provide effective treatments that address the unmet medical needs of individuals suffering from these debilitating conditions.

EUM provides a residential management platform that utilizes AI-driven tools for efficient defect reporting and maintenance coordination, enabling residents to easily register issues through voice recognition and QR code scanning. The service connects residents with property managers, ensuring timely repairs and enhancing overall living quality in newly constructed apartments.

This startup is developing protein therapeutics specifically designed to treat severe allergic diseases by targeting and modulating immune responses. Their approach aims to provide effective treatment options for patients who suffer from debilitating allergic reactions.

Inverna Therapeutics is developing an RNA splicing modulation platform that targets pseudo-exons to enable precise, allele-specific therapeutic interventions with minimal off-target effects. The platform's lead program focuses on Huntington's disease, leveraging a vast database of potential pseudo-exon targets to enhance treatment efficacy.

Kivu Bioscience develops next-generation antibody-drug conjugates (ADCs) utilizing site-specific conjugation technology, specifically targeting asparagine-297 to enhance homogeneity and stability while minimizing off-target toxicity. The company addresses the need for more effective cancer treatments by creating highly stable ADCs with optimized linker and payload combinations that improve therapeutic efficacy and patient tolerability.

Magnus Medical develops the SAINT neuromodulation system, which utilizes structural and functional MRI to identify optimal therapy targets in the brain for personalized treatment of severe depression. By applying a non-invasive pattern of repetitive magnetic pulses, SAINT modifies brain network activity, effectively restoring mood balance in individuals with intractable neurological and psychiatric disorders.

O is developing an IoT device that visualizes the human circadian clock to enhance individual and organizational performance through data-driven insights. The platform provides actionable recommendations based on sleep data, addressing productivity issues and mental health risks within teams.

Develops bispecific therapeutic antibodies that engage immune cells to target and eliminate solid tumors, particularly those resistant to immune checkpoint inhibitors. By optimizing the potencies of immune-engaging arms and improving tumor localization, these antibodies aim to provide effective treatment with reduced side effects, addressing critical gaps in cancer immunotherapy.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.